Dados do Trabalho

Título

Oral treatment with cannabinoids microdosing improves sleep in Parkinson Diseases - Preliminary Findings

Introdução

Sleep disorders (SD) are very common and can occur before the beginning of motor symptoms in Parkinson's disease (PD) patients. Current therapies to treat SD in PD patients are very ineffective. On the other hand, several studies have shown the potential of Cannabis sativa (CS) and cannabinoids to treat SD in many kind of patients. Then, our hypothesis is that CS treatment could improve the SD in PD patients

Objetivo

To evaluate the effect of a CS extract with cannabinoids low doses on SD in PD patients

Métodos

Four patient diagnosed with PD for at least 10 years were selected. The project was approved by the Human Ethics Committee. 3 patients underwent an oral oil containing 1mg THC and 112µg CBD daily while 1 patient received the oil containing 250µg THC and 28µg CBD, daily. The treatment lasted for 60 days. During this period, patients used an actimeter on non-dominant wrist to monitor the following parameters: bed time, wake up time, time in bed, sleep duration, sleep efficiency, number of awakenings and WASO. A total of 33 days of actigraphy per subject was considered for this exploratory analysis, resulting in 132 nights evaluated in three times (T1=48 nights, T2=48 nights, and T3=36 nights). Due the small sample size, the nights were considered as independent measures and means were compared using factorial ANOVA, with dose time of evaluation as between factors. Values are presented as means±SE

Resultados

Patient aged from 49-65 years old. ANOVA did not identified effects of dose, or time of treatment for Bedtime (1mg 21:42±00:07; 250 21:52±00:12, p>0.05), time in bed (1mg 08:05±0:08; 250 07:45±00:14; p>0.05). However, there was significant effect of dose and time of treatment for the waking up time at with earlier waking up for the 250 g at the T3 (1mg 5:38±0:13; 250 4:32±0:23; p<0.05). The lower dose of treatment also was associated with shorter sleep duration, with ANOVA detecting effect of dose (1mg 6:51±0:07; 250 6:00±00:12; p<0.05). Dose was associated with increasing sleep efficiency for the 250 condition, from 75.75%±2.36 at T1 to 82.2.37%±2.73 at T3, as a consequence of reduced WASO from T1 to T3 (115.91±10.5min to 77.22±12.54min p<0.05).

Conclusões

Our preliminary findings suggest that cannabinoids microdosing have potential as a pharmacological tool to treat SD with significant benefits in sleep characteristics. Notwithstanding, further studies with larger sample sizes are needed

Palavras-chave

Parkinson Disease, Cannabinoids, microdosing, sleep disorders

Área

Área Clínica